Kairos Pharma Ltd. (NYSE American: KAPA) has been named a winner in the 2026 GHP Magazine Healthcare & Pharmaceutical Awards, receiving recognition as the USA leader in drug resistance development. The award underscores the company’s focus on advancing cancer therapeutics designed to address treatment resistance, a critical challenge in oncology that limits the effectiveness of existing therapies.
The award highlights Kairos Pharma’s innovative approach to extending the effectiveness of standard cancer treatments by targeting the mechanisms that drive drug resistance. According to the company, its lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
ENV-105 is currently being evaluated in clinical trials. It is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any comparable foreign regulator.
The importance of this award lies in the growing recognition of drug resistance as a major hurdle in cancer treatment. Many patients initially respond to therapy but later experience relapse due to resistance, which can render standard treatments ineffective. Kairos Pharma’s work on ENV-105 represents a potential strategy to overcome this challenge, offering hope for improved outcomes in cancers like prostate and lung cancer, which are among the most common and deadly worldwide.
The award from GHP Magazine places Kairos Pharma among leaders in healthcare innovation, particularly in the field of drug resistance. For the industry, this recognition may draw attention to the need for therapies that address resistance mechanisms, potentially influencing research priorities and investment in similar approaches. For patients and healthcare providers, the development of drugs like ENV-105 could mean more durable responses to treatment and improved quality of life.
Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company’s newsroom provides updates on its progress, accessible at https://ibn.fm/KAPA. The full press release regarding the award is available at https://ibn.fm/WuBOf.
As Kairos Pharma advances its clinical trials, the implications of its research extend beyond individual patients. If successful, ENV-105 could become a cornerstone in combination therapies, helping to prolong the efficacy of existing drugs and reduce the frequency of resistance-driven relapses. The award serves as a testament to the potential of this approach and the urgency of addressing drug resistance in cancer care.
